The five-year survival rate for high expressers is 55% versus 67% for low expressers in ccRCC patients, though there were no statistical differences in five-year survival rates for pRCC (p = 0.072) and chRCC (p = 0.25) patients. Here, PRCC is linked to nonpapillary renal cell carcinoma.